>latest-news

Turn Therapeutics Expands Leadership Team With Appointment Of Martin Dewhurst To Its Board

Turn Therapeutics strengthens its Board with Martin Dewhurst, bringing deep M&A and life sciences leadership.

Breaking News

  • Jan 08, 2026

  • Simantini Singh Deo

Turn Therapeutics Expands Leadership Team With Appointment Of Martin Dewhurst To Its Board

cccccccccccTurn Therapeutics Inc., a clinical-stage biotechnology company focused on developing targeted inflammatory and immunology therapies for dermatology, advanced wound care, and infectious diseases, has announced the appointment of Mr. Martin Dewhurst to its Board of Directors. Mr. Dewhurst brings over 30 years of global leadership experience in the life sciences sector, with a strong background in mergers and acquisitions.


Bradley Burnam, Chief Executive Officer of Turn Therapeutics, said that Martin’s addition to the Board comes at an important time for the company as it executes a disciplined, M&A-driven strategy aimed at strengthening its pipeline and supporting long-term value creation. He noted that Mr. Dewhurst’s extensive experience in capital allocation, portfolio development, and strategic partnerships will provide valuable insight as the company evaluates opportunities that fit its growth ambitions and enhance its platform.


During his three decades at McKinsey & Company, Mr. Dewhurst co-led the firm's global life sciences practice and advised companies across biopharmaceuticals, medical technology, genetics, and consumer health. He later co-founded and led the McKinsey Health Institute, a nonprofit initiative addressing global health challenges.


Expressing his enthusiasm for the new role, Mr. Dewhurst said he is pleased to join Turn Therapeutics at a meaningful point in its growth journey. He emphasized that the company has built a strong and differentiated platform aimed at addressing significant unmet needs across dermatology, wound care, and infectious disease. He added that he looks forward to supporting the Board and management team in executing the company’s strategic priorities, including targeted portfolio expansion, value-driving partnerships, and thoughtful acquisitions, to help guide sustainable growth.


Beyond his consulting career, Mr. Dewhurst serves as a senior advisor to PJT Partners, a global investment and mergers and acquisitions advisory firm. He is also an external partner at Lightrock, a growth-stage impact investment firm, and holds board positions including at Distalmotion, a Switzerland-based medical technology company specializing in robotic surgery. He is also a regular contributor and speaker at prominent global forums such as Bloomberg New Economy, the Milken Institute, the Financial Times, and The Economist. Mr. Dewhurst completed his undergraduate studies at Magdalen College, University of Oxford, and earned his MBA from INSEAD, where he graduated on the Dean’s List.

Ad
Advertisement